Loxapine Succinate (loxapine succinate)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Loxapine is a tricyclic dibenzoxazepine-derivative antipsychotic agent. The drug is considered a conventional or first-generation antipsychotic agent.
USES: This medication is used to treat certain mental/mood disorders (such as schizophrenia). Loxapine belongs to a class of drugs known as antipsychotics. It works by helping to restore the balance of certain natural substances in the brain.
Generic name: loxapine succinate
Pronunciation: (LOX-uh-peen)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Loxapine Succinate
Indications
The following indications are listed for Loxapine Succinate:
- Schizophrenia
Also known as: Dementia Praecox, Parergasia.
Dosing
Although USP currently states that potency of loxapine succinate preparations should be expressed in terms of both the salt and the base (''active moiety''), dosage currently is expressed in terms of the base. (See Chemistry and Stability: Chemistry.) Dosage must be carefully adjusted according to individual requirements and response using the lowest possible effective dosage.
Loxapine succinate is administered orally. Loxapine hydrochloride has been administered orally or by IM injection, but loxapine hydrochloride no longer is commercially available in the US.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Neonates exposed to antipsychotic agents during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Symptoms reported in these neonates to date include agitation, hypertonia, hypotonia, tardive dyskinetic-like symptoms, tremor, somnolence, respiratory distress, and feeding disorder. Any neonate exhibiting extrapyramidal or withdrawal symptoms following in utero exposure to antipsychotic agents should be monitored. Symptoms were self-limiting in some neonates, but varied in severity; some infants required intensive care unit support and prolonged hospitalization. For further information on extrapyramidal and withdrawal symptoms in neonates, see Cautions: Pregnancy, Fertility, and Lactation, in the Phenothiazines General Statement 28:16.08.24.
Safe use of loxapine during pregnancy has not been established; therefore, the drug should not be used in pregnant women or women who might become pregnant unless the potential benefits outweigh the possible risk to the woman or fetus.
The extent of distribution of loxapine and/or its metabolites into human milk is not known, but the drug and its metabolites distribute into milk in lactating dogs. The manufacturers recommend that use of loxapine in nursing women be avoided if clinically possible.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.